But this week, a new WHO decision has cast fresh doubt on the continued efficacy of Chinese-made vaccines for many millions who had received them. The new recommendation means people who had received two doses of either Sinopharm or Sinovac could seek third doses, potentially of another vaccine, constraining an already limited global supply.